GlassScriptPhysician profile
George M Zlupko
NPI 1902867716
$26,151.32
in general payments reported to CMS, 2019-2025
52 companies · $3,523 in 2025
The $3,523 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,411 · 2020: $2,256 · 2021: $2,937 · 2022: $2,612 · 2023: $2,783 · 2024: $3,630 · 2025: $3,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,681 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,680.77 |
| Education | $254.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $6,087.90 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $4,477.14 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $3,139.91 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,336.23 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Genzyme Corporation | $1,034.90 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $994.40 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $859.15 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $777.34 | 2019-2024 | Xywav |
| United Therapeutics Corporation | $732.95 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Electromed, INC. | $547.16 | 2019-2025 | Smartvest |
| Pfizer INC. | $506.26 | 2019-2021 | |
| Grifols USA, LLC | $480.10 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $465.23 | 2019-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $437.56 | 2019-2025 | Xolair |
| Philips North America LLC | $353.35 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $327.16 | 2019-2021 | |
| Harmony Biosciences LLC | $305.55 | 2020-2025 | Wakix |
| Merck Sharp & Dohme LLC | $296.50 | 2019-2025 | Winrevair, Belsomra, Keytruda |
| Resmed Corp | $284.68 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.74 | 2020-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $233.68 | 2020-2024 | Acthar |
| Amgen INC. | $217.35 | 2022-2025 | Tezspire |
| Axsome Therapeutics, INC. | $198.65 | 2024-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $187.75 | 2024-2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $187.02 | 2019-2025 | |
| Inspire Medical Systems, INC. | $162.30 | 2023-2025 | Inspire |
| Advanced Respiratory, INC | $156.40 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $134.98 | 2022-2023 | |
| Abbvie INC. | $120.82 | 2021-2024 | Avycaz, Dalvance, Teflaro |
| Pulmonx Corporation | $84.22 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Zoll Respicardia, INC. | $81.42 | 2022 | |
| Verona Pharma, INC. | $74.57 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $74.50 | 2021-2022 | |
| Baxter Healthcare | $61.90 | 2022-2023 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Allergan, INC. | $54.54 | 2019-2020 | |
| Tactile Systems Technology INC | $39.13 | 2025 | Nimbl, Flexitouch Plus |
| Vapotherm INC | $35.78 | 2021-2022 | |
| Smith+Nephew, INC. | $32.49 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.09 | 2020-2023 | |
| Optinose US, INC. | $29.70 | 2021 | |
| Ani Pharmaceuticals, INC. | $27.66 | 2025 | Purified Cortrophin Gel |
| 3b Medical, INC. | $25.50 | 2025 | Luna |
| Reddress USA, INC. | $22.07 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.08 | 2023 | Nuzyra |
| Viatris Specialty LLC | $20.59 | 2025 | Yupelri |
| Seqirus USA INC | $19.49 | 2025 | Flucelvax, Fluad |
| Eisai INC. | $19.21 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.83 | 2023 | Quviviq |
| Shire North American Group INC | $15.77 | 2019 | |
| Lilly USA, LLC | $14.97 | 2025 | Zepbound |
| Alexion Pharmaceuticals, INC. | $14.79 | 2020 | |
| Circassia INC. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Zlupko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.